anti-Human CD55 antibody for ELISA (Detection)

Recommended CD55 Antibody (supplied by: Log in to see )

Antigen
Complement Decay-Accelerating Factor (CD55) Antibodies
  • Daf
  • Daf-GPI
  • Daf1
  • GPI-DAF
  • CR
  • CROM
  • DAF
  • TC
  • AI323748
  • Cd55b
  • Daf-TM
  • TM-DAF
  • CD55 antigen
  • CD55 molecule, decay accelerating factor for complement (Cromer blood group)
  • decay accelerating factor 2
  • Cd55
  • CD55
  • Daf2
Epitope
AA 1-353
18
11
10
9
9
8
8
8
8
5
5
4
4
4
3
3
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
Reactivity
Human
412
56
22
9
9
4
3
2
2
2
Host
Mouse
338
97
24
8
7
3
3
Clonality
Monoclonal
Conjugate
This CD55 antibody is un-conjugated
53
47
30
13
11
11
10
9
8
8
6
6
6
6
6
6
5
5
5
4
4
4
3
3
2
2
1
1
1
Application
ELISA, ELISA (Detection)
360
186
97
63
57
54
42
39
12
8
6
6
6
5
2
2
1
1
1
1
Supplier
Log in to see
Supplier Product No.
Log in to see
Request

Get this product for free

Submit your validation data for this product and get a full refund. I want to validate this product

Learn more

Catalog No. ABIN1995653
$ 218.90
Plus shipping costs $45.00

General

Antigen Complement Decay-Accelerating Factor (CD55) Antibodies
Epitope AA 1-353
(18), (11), (10), (9), (9), (8), (8), (8), (8), (5), (5), (4), (4), (4), (3), (3), (2), (2), (2), (2), (2), (2), (2), (1), (1), (1), (1), (1), (1), (1), (1)
Reactivity Human
(412), (56), (22), (9), (9), (4), (3), (2), (2), (2)
Host Mouse
(338), (97), (24), (8), (7), (3), (3)
Clonality (Clone)
Monoclonal   ( )
Conjugate This CD55 antibody is un-conjugated
(53), (47), (30), (13), (11), (11), (10), (9), (8), (8), (6), (6), (6), (6), (6), (6), (5), (5), (5), (4), (4), (4), (3), (3), (2), (2), (1), (1), (1)
Application ELISA, ELISA (Detection)
(360), (186), (97), (63), (57), (54), (42), (39), (12), (8), (6), (6), (6), (5), (2), (2), (1), (1), (1), (1)
Pubmed 3 references available
Supplier Log in to see

Product Details anti-CD55 Antibody

Target Details CD55 Application Details Handling ProductDetails: References for anti-CD55 antibody (ABIN1995653) Images
Specificity Human CD55 / DAF
No cross-reactivity with Human cell lysate (293 cell line) in WB and ELISA.
No Cross-Reactivity Human
Characteristics This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human CD55 / DAF (rh CD55, ABIN2002066 NP_000565.1, Met 1-Ser 353,. The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.
Purification purified by Protein A affinity chromatography
Sterility 0.2 μm filtered
Immunogen Recombinant Human CD55 protein (ABIN2002066)
Clone 4C10H10B7
Isotype IgG1

Target Details CD55

Product Details anti-CD55 Antibody Application Details Handling ProductDetails: References for anti-CD55 antibody (ABIN1995653) Images back to top
Antigen
Alternative Name CD55 (CD55 Antibody Abstract)
Background CD55, also well known as decay-accelerating factor (DAF), is a member of the RCA (regulators of complement activation) family characterized by four to 30 SCRs (short consensus repeats) in their plasma-exposed regions. It is a major regulator of the alternative and classical pathways of complement activation and is expressed on all serum-exposed cells. CD55 is physiologically acting as an inhibitor of the complement system, but is also broadly expressed in malignant tumours. DAF seems to exert different functions beyond its immunological role such as promotion of tumorigenesis, decrease of complement mediated tumor cell lysis, autocrine loops for cell rescue and evasion of apoptosis, neoangiogenesis, invasiveness, cell motility. It is commonly hijacked by invading pathogens, including many enteroviruses and uropathogenic Escherichia coli, to promote cellular attachment prior to infection. This 70-75 kDa glycoprotein CD55 containing four SCR modules is involved in the regulation of the complement cascade. It inhibits complement activation by suppressing the function of C3/C5 convertases, thereby limiting local generation or deposition of C3a/C5a and membrane attack complex (MAC or C5b-9) production. DAF has been identified as a ligand for an activation-associated, seven-transmembrane lymphocyte receptor, CD97, which is a receptor mediating attachment and infection of several viruses and bacteria. In addition, it has been shown that DAF regulates the interplay between complement and T cell immunity in vivo, and thus may be implicated in immune and tumor biology.
NCBI Accession NP_000565.1
Research Area Immunology, CD Antigens, Surface Receptors of Immune Cells
Pathways Complement System, Regulation of Leukocyte Mediated Immunity

Application Details

Product Details anti-CD55 Antibody Target Details CD55 Handling ProductDetails: References for anti-CD55 antibody (ABIN1995653) Images back to top
Application Notes ELISA: 0.5-1.0 μg/mL
This antibody can be used at 0.5-1.0 μg/mL with the appropriate secondary reagents to detect Human CD55. The detection limit for Human CD55 is 0.078 ng/well.
ELISA(Det): 0.1-1 μg/mL
Restrictions For Research Use only

Handling

Product Details anti-CD55 Antibody Target Details CD55 Application Details ProductDetails: References for anti-CD55 antibody (ABIN1995653) Images back to top
Format Liquid
Buffer 0.2 μm filtered solution in PBS with 5 % trehalose
Preservative Without preservative
Handling Advice Avoid repeated freeze-thaw cycles.
Storage 4 °C,-20 °C,-80 °C
Storage Comment This antibody can be stored at 2°C-8°C for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20°C to -80°C. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
Expiry Date 12 months

ProductDetails: References for anti-CD55 antibody (ABIN1995653)

Product Details anti-CD55 Antibody Target Details CD55 Application Details Handling Images back to top
Background publications

Mikesch, Schier, Roetger, Simon, Buerger, Brandt: "The expression and action of decay-accelerating factor (CD55) in human malignancies and cancer therapy." in: Cellular oncology : the official journal of the International Society for Cellular Oncology, Vol. 28, Issue 5-6, pp. 223-32, 2006

Mikesch, Schier, Roetger, Simon, Buerger, Brandt: "The expression and action of decay-accelerating factor (CD55) in human malignancies and cancer therapy." in: Cellular oncology : the official journal of the International Society for Cellular Oncology, Vol. 28, Issue 5-6, pp. 223-32, 2006

Lea: "Interactions of CD55 with non-complement ligands." in: Biochemical Society transactions, Vol. 30, Issue Pt 6, pp. 1014-9, 2002